Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. (BLLN) filed a Form 4 reporting equity award activity for its Chief Financial Officer. The filing shows stock options with exercise prices of $11.55 and $30.78 covering 175,000 and 75,000 shares, respectively. These options are listed both before and after a reclassification in connection with the company’s initial public offering of Class A common stock.
The filing explains that, under a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically converted into one share of Class A common stock immediately prior to completion of the IPO. The $11.55 options vest over four years, with 25% vested on January 8, 2025 and the rest in monthly installments over three years. The $30.78 options vest in equal monthly installments over four years starting September 15, 2025, contingent on continued service.